ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Sold by Point72 Asia Singapore Pte. Ltd.

Point72 Asia Singapore Pte. Ltd. reduced its stake in shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT) by 7.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 27,045 shares of the company’s stock after selling 2,075 shares during the quarter. Point72 Asia Singapore Pte. Ltd.’s holdings in ClearPoint Neuro were worth $416,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in CLPT. R Squared Ltd acquired a new position in shares of ClearPoint Neuro in the 4th quarter valued at $32,000. AlphaQuest LLC acquired a new position in shares of ClearPoint Neuro during the 4th quarter valued at about $80,000. Barclays PLC increased its holdings in shares of ClearPoint Neuro by 24.3% during the 3rd quarter. Barclays PLC now owns 5,674 shares of the company’s stock valued at $64,000 after acquiring an additional 1,109 shares during the last quarter. Tower Research Capital LLC TRC acquired a new position in shares of ClearPoint Neuro during the 4th quarter valued at about $93,000. Finally, JPMorgan Chase & Co. grew its holdings in ClearPoint Neuro by 58.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 9,770 shares of the company’s stock valued at $110,000 after buying an additional 3,612 shares during the last quarter. 30.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Stifel Nicolaus lifted their price objective on ClearPoint Neuro from $19.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, April 1st. Lake Street Capital lifted their price objective on ClearPoint Neuro from $17.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, January 21st. Finally, B. Riley boosted their target price on ClearPoint Neuro from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday, January 28th.

ClearPoint Neuro Stock Performance

CLPT opened at $12.92 on Friday. ClearPoint Neuro, Inc. has a 52-week low of $5.11 and a 52-week high of $19.22. The firm has a market capitalization of $361.62 million, a PE ratio of -18.72 and a beta of 1.03. The business’s 50-day simple moving average is $12.86 and its 200 day simple moving average is $14.22.

ClearPoint Neuro (NASDAQ:CLPT) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.07). ClearPoint Neuro had a negative net margin of 59.64% and a negative return on equity of 62.10%. The business had revenue of $8.49 million during the quarter, compared to the consensus estimate of $8.21 million. On average, research analysts forecast that ClearPoint Neuro, Inc. will post -0.66 earnings per share for the current year.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.